Literature DB >> 24284734

Sarcomatoid carcinoma in head and neck: a review of 30 years of experience--clinical outcomes and reconstructive results.

Nai-Jen Chang1, Dennis S Kao, Li-Yu Lee, John Wen-Cheng Chang, Ming-Mo Hou, Wee Leon Lam, Ming-Huei Cheng.   

Abstract

PROBLEM PRESENTED: Sarcomatoid carcinoma (SaCa) is a rare variant of squamous cell carcinoma (SCC) with sarcomatoid features. This study investigated the clinical presentation and outcomes of head and neck SaCa. In addition, reconstructive outcome for a subset of patients was also evaluated. STUDIES UNDERTAKEN: Seventy-eight SaCa cases including 72 men and 6 women were identified from 13,777 head and neck SCC cases. Clinical outcomes were evaluated based on locoregional control, distant metastases, and multivariate analyses. Reconstructive outcome was evaluated by flap survival rate. RESULT: Of the 78 cases, 71% (55) of cases were located in the oral mucosa; 64% (50) of patients were classified as T3 or T4 at the time of diagnosis. The 5-year survival was only 16%. Multivariate analysis revealed better outcomes only when the patient had a history of previous SCC. Forty-five patients underwent flap reconstruction, with 98% flap survival rate but the functional result varied because of the inevitable adjuvant radiotherapy and advanced stage of tumor.
CONCLUSIONS: Sarcomatoid carcinoma is a different entity from the conventional SCC of the head and neck. Sarcomatoid carcinoma carries a poorer prognosis despite aggressive surgical intervention and concurrent adjuvant therapies. It remains a great challenge for clinical oncologists, and the optimal treatment strategy requires further studies. Free flap is still preferred for defect reconstruction but the design should be simplified to avoid complications.

Entities:  

Mesh:

Year:  2013        PMID: 24284734     DOI: 10.1097/SAP.0000000000000069

Source DB:  PubMed          Journal:  Ann Plast Surg        ISSN: 0148-7043            Impact factor:   1.539


  8 in total

1.  Oral sarcomatoid squamous cell carcinoma: a retrospective study based on 14 cases.

Authors:  Jialiang Liu; Meng Xiao; Yan'an Wang
Journal:  Histol Histopathol       Date:  2019-10-23       Impact factor: 2.303

2.  Spindle Cell Squamous Cell Carcinoma of Head and Neck Region: a Clinicopathological and Immunohistochemical Study.

Authors:  Bakshi Neha; Dhawan Shashi; Rao Seema
Journal:  Indian J Surg Oncol       Date:  2021-08-17

3.  Clinicopathologic features and outcome of head and neck mucosal spindle cell squamous cell carcinoma.

Authors:  Carlos N Prieto-Granada; Bin Xu; Bayan Alzumaili; Mohamed Rizwan Haroon Al Rasheed; Antoine Eskander; Danny Enepekides; Snehal G Patel; Todd M Stevens; Snjezana Dogan; Ronald Ghossein; Nora Katabi
Journal:  Virchows Arch       Date:  2021-05-12       Impact factor: 4.535

4.  Spindle cell carcinoma: the general demographics, basic clinico-pathologic characteristics, treatment, outcome and prognostic factors.

Authors:  Lei Feng; Deng Cai; Alanuer Muhetaer; Yin-Long Yang; Fei Ren; Mumingjiang Yishake; Hao Zhang; Yuan Fang; Alimujiang Wushou
Journal:  Oncotarget       Date:  2017-06-27

5.  Oncologic Outcomes of Patients With Sarcomatoid Carcinoma of the Hypopharynx.

Authors:  Liyuan Dai; Qigen Fang; Peng Li; Fei Liu; Xu Zhang
Journal:  Front Oncol       Date:  2019-09-24       Impact factor: 6.244

6.  Sarcomatoid Carcinoma in the Head and Neck: A Population-Based Analysis of Outcome and Survival.

Authors:  Lin Ding; Zhuo-Fei Bi; Hang Yuan; Xiao-Hui Zhao; Xue-Dan Guan; He-Rui Yao; Yi-Min Liu
Journal:  Laryngoscope       Date:  2020-07-21       Impact factor: 3.325

7.  A Rare Case of Neck Sarcomatoid Squamous Cell Carcinoma With Brain Metastases.

Authors:  Ipsit Shah; Abrahim N Razzak; Abhishek Janardan; Brandon Laing; Nathan T Zwagerman
Journal:  Cureus       Date:  2022-06-21

8.  Sinonasal spindle cell carcinoma presenting with bilateral visual loss: A case report and review of the literature.

Authors:  Tsung-Wei Liu; Shih-Han Hung; Po-Yueh Chen
Journal:  Oncol Lett       Date:  2016-05-25       Impact factor: 2.967

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.